Fachklinik Hornheide e.V.

The trials here

What the 10 trials at this site are about, from their registry records.

Conditions

• Melanoma10 trials
• Childhood cancers3 trials

Phase

• Phase 35 trials
• Phase 12 trials
• Phase 22 trials
• Phase 2/31 trial

Status

• Completed5 trials
• Recruiting3 trials
• Active, not recruiting2 trials

Lead sponsor

• Regeneron Pharmaceuticals2 trials
• Eikon Therapeutics1 trial
• Erasca, Inc.1 trial
• Genmab A/S1 trial
• H e x a l AG1 trial
• and 4 more

Running trials

• Recruiting

  A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors

  NCT07600476· Phase 1· Kupando GmbH· Source

• Recruiting

  Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

  NCT06697301· Phase 2/3· Eikon Therapeutics· Source

• Active, not recruiting

  A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

  NCT05608291· Phase 3· Regeneron Pharmaceuticals· Source

• Active, not recruiting

  Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

  NCT05352672· Phase 3· Regeneron Pharmaceuticals· Source

• Active, not recruiting

  Adjuvant Nivolumab Treatment in Stage II (IIA, IIB, IIC) High-risk Melanoma

  NCT04309409· Phase 3· University Hospital, Essen· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Melanoma3 recruiting
• Childhood cancers2 recruiting

Closed trials

• Completed

  Study of the Effectiveness and Safety of Acasunlimab Alone or With Pembrolizumab in treating Advanced Melanoma of the Skin That Has Returned After or did not respond to Cancer Immunotherapy (ABBIL1TY MELANOMA-07)

  NCT06984328· Phase 2· Genmab A/S· Source

• Completed

  A Pharmacokinetics (PK) study to compare GME751 (proposed pembrolizumab biosimilar) and United States (US)-licensed and European Union (EU)-approved Keytruda®in participants with stage Ⅱ and Ⅲ skin cancer requiring adjuvant treatment (therapy applied after initial treatment of cancer to suppress the regrowth of tumor) with pembrolizumab.

  2023-506881-30-00· Phase 1· H e x a l AG· Source

• Active, not recruiting

  A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

  NCT06346067· Phase 3· Erasca, Inc.· Source

• Completed

  Phase 2 Study of Encorafenib and Binimetinib Plus Pembrolizumab in Participants With BRAF V600E/K Mutation-Positive Melanoma Who Progressed During or After Prior Treatment with Anti−PD-1 Therapy

  2023-509471-17-00· Phase 2· Pfizer Inc.· Source

• Active, not recruiting

  A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

  NCT04657991· Phase 3· Pfizer· Source